HCi Viocare awarded Start-Up Grant for the 10th International Conference on Advanced Technologies & Treatments for Diabetes

HCi Viocare has been recognized for its contribution to the development of innovative solutions in the diabetes prevention and treatment fields by being awarded a Startup Grant for the Technology Fair at the 10th International Conference on Advanced Technologies & Treatments for Diabetes(ATTD).

 

The Conference will take place in Paris, France on February 15th-18th, 2017. Over the past 9 years, the International Conference of ATTD has become synonymous with top caliber scientific programs that have provided participants with cutting edge research and analysis into the latest developments in diabetes-related technology. With 2,645 participants from 80 countries, the unique and innovative Conference, substanialy contributes to the exchange of ideas and information related to the technology, treatment and prevention of diabetes and related illnesses.

 

HCi Viocare has been distinguished for its innovative solution, the Flexisense™ technology,  which addresses important gaps in the diabetes care field. 

 

The Company's awarded participation at the ATTD Conference include a booth in which the Company will demonstrate the unique features of the Flexisense™ Smart Insole, and a related presentation at the Technology Fair.

 

HCi Viocare’s co-founder and CTO, Dr Christos Kapatos stated: “We are honored to be a sponsored participant at the ATTD Conference and to be given the opportunity to demonstrate our diabetic foot ulceration prevention technology. Our Flexisense™ Smart Insole is designed to substantially improve care for people with diabetes, by helping them protect their feet, without interrupting their lifestyle.”